Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Depreciation & Amortization (CF) (2016 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Depreciation & Amortization (CF) for 14 consecutive years, with $19000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Depreciation & Amortization (CF) fell 76.54% year-over-year to $19000.0, compared with a TTM value of $296000.0 through Dec 2025, down 12.94%, and an annual FY2025 reading of $296000.0, down 12.94% over the prior year.
  • Depreciation & Amortization (CF) was $19000.0 for Q4 2025 at Karyopharm Therapeutics, down from $121000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $290000.0 in Q1 2023 and bottomed at $19000.0 in Q4 2025.
  • Average Depreciation & Amortization (CF) over 5 years is $128800.0, with a median of $102000.0 recorded in 2022.
  • The sharpest move saw Depreciation & Amortization (CF) soared 63.84% in 2023, then crashed 76.54% in 2025.
  • Year by year, Depreciation & Amortization (CF) stood at $139000.0 in 2021, then fell by 18.71% to $113000.0 in 2022, then crashed by 31.86% to $77000.0 in 2023, then increased by 5.19% to $81000.0 in 2024, then crashed by 76.54% to $19000.0 in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for KPTI at $19000.0 in Q4 2025, $121000.0 in Q3 2025, and $78000.0 in Q2 2025.